Kiora director granted 25,000 stock options
Kiora Pharmaceuticals director Aron Shapiro received a grant of stock options as part of equity compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Kiora Pharmaceuticals director Aron Shapiro received a grant of stock options as part of equity compensation. The award covers 25,000 options for Common Stock at an exercise price of $2.63 per share, becomes fully exercisable on June 10, 2027, and expires on June 10, 2036.
Insider Trade Summary
Grant/Award: 25,000 shares
Grant/Award
1 txn
Insider
Shapiro Aron
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 25,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 25,000 contracts (Direct)
Footnotes (1)
- F1. The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027.
Key Figures
Options granted: 25,000 options
Exercise price: $2.63 per share
Vesting date: June 10, 2027
+3 more
6 metrics
Options granted
25,000 options
Stock Option (right to buy) granted to director
Exercise price
$2.63 per share
Conversion or exercise price for Common Stock
Vesting date
June 10, 2027
Options become fully exercisable on this date
Expiration date
June 10, 2036
Unexercised options lapse after this date
Underlying shares
25,000 shares
Underlying Common Stock tied to the option grant
Post-grant derivative holdings
25,000 options
Total stock options held following transaction
Key Terms
Stock Option (right to buy), 2024 Equity Incentive Plan, exercise price, Common Stock
4 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
2024 Equity Incentive Plan financial
"pursuant to the Issuer's 2024 Equity Incentive Plan."
exercise price financial
"conversion_or_exercise_price: "2.6300""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Kiora Pharmaceuticals (KPRX) director Aron Shapiro report on this Form 4?
Aron Shapiro reported receiving a grant of 25,000 stock options for Kiora Pharmaceuticals Common Stock. These options were issued under the company’s 2024 Equity Incentive Plan as compensation, not through an open-market purchase or sale of existing shares.
What are the key terms of Aron Shapiro’s KPRX stock option grant?
The grant covers 25,000 stock options with an exercise price of $2.63 per share. The options relate to Kiora Pharmaceuticals Common Stock and were awarded with no cash paid upfront, reflecting a compensation-related award rather than a market transaction.
When do Aron Shapiro’s Kiora Pharmaceuticals options vest and become exercisable?
The options become fully exercisable on June 10, 2027. Until that vesting date, Shapiro cannot exercise them to buy Common Stock. This single vesting date structure means the full award becomes available at once rather than in installments.
When do the KPRX stock options granted to Aron Shapiro expire?
The stock options expire on June 10, 2036 if not exercised earlier. After this expiration date, any unexercised options will lapse and no longer allow purchase of Kiora Pharmaceuticals Common Stock at the $2.63 exercise price.
How many Kiora Pharmaceuticals options does Aron Shapiro hold after this Form 4 transaction?
Following this grant, Shapiro holds 25,000 stock options directly according to the filing. These options give him the right to buy an equal number of Kiora Pharmaceuticals Common Stock shares at $2.63 per share once they vest.
Was Aron Shapiro’s KPRX stock option grant made under a company equity plan?
Yes. The filing states the option grant was issued under Kiora Pharmaceuticals’ 2024 Equity Incentive Plan. Such plans are commonly used by companies to grant stock-based compensation to directors, executives, and employees to align incentives with shareholders.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates